Animal model of methylphenidate's long-term memory-enhancing effects

Learning and Memory

Volumn 21, Issue 2, 2014, Pages 82-89

  Carmack, Stephanie A ^a   Howell, Kristin K ^a   Rasaei, Kleou ^a   Reas, Emilie T ^b   Anagnostaras, Stephan G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE; ANIMALS; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CITALOPRAM; COCAINE; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FEMALE; LOCOMOTION; MALE; MAZE LEARNING; MEMORY, LONG-TERM; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; NOOTROPIC AGENTS; PROPYLAMINES; REINFORCEMENT (PSYCHOLOGY); SEROTONIN UPTAKE INHIBITORS; SPACE PERCEPTION;

EID: 84894236394     PISSN: 10720502     EISSN: 15495485     Source Type: Journal    
DOI: 10.1101/lm.033613.113     Document Type: Article

References (63)

1. Abraham AD, Cunningham CL, Lattal KM. 2012. Methylphenidate enhances extinction of contextual fear. Learn Mem 19: 67-72.
2. Akirav I, Richter-Levin G. 2002. Mechanisms of amygdala modulation of hippocampal plasticity. J Neurosci 22: 9912-9921.
3. Anagnostaras SG, Maren S, Fanselow MS. 1999. Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: Within-subjects examination. J Neurosci 19: 1106-1114.
4. Anagnostaras SG, Josselyn SA, Frankland PW, Silva AJ. 2000. Computer-assisted behavioral assessment of Pavlovian fear conditioning in mice. Learn Mem 7: 58-72.
5. Anagnostaras SG, Gale GD, Fanselow MS. 2001. Hippocampus and contextual fear conditioning: Recent controversies and advances. Hippocampus 11: 8-17.
6. Anagnostaras SG, Wood SC, Shuman T, Cai DJ, Leduc AD, Zurn KR, Zurn JB, Sage JR, Herrera GM. 2010. Automated assessment of pavlovian conditioned freezing and shock reactivity in mice using the video freeze system. Front Behav Neurosci 4: 1-11.
7. Arnsten AF. 2006. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31: 2376-2383.
8. Arnsten AF, Dudley AG. 2005. Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1: 2-10.
9. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. 2003. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54: 1465-1468.
10. Barkley RA. 1997. Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychol Bull 121: 65-94.
11. Barkley RA. 1998. Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. Guilford Press, New York.
12. Berridge CW, Devilbiss DM. 2011. Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol Psychiatry 69: e101-e111.
13. Berridge CW, Shumsky JS, Andrzejewski ME, McGaughy JA, Spencer RC, Devilbiss DM, Waterhouse BD. 2012. Differential sensitivity to psychostimulants across prefrontal cognitive tasks: Differential involvement of noradrenergic a1-and a2-receptors. Biol Psychiatry 71: 467-473.
14. Braver TS, Barch DM, Kelley WM, Buckner RL, Cohen NJ, Miezin FM, Snyder AZ, Ollinger JM, Akbudak E, Conturo TE, et al. 2001. Direct comparison of prefrontal cortex regions engaged by working and long-term memory tasks. Neuro Image 14: 48-59.
15. Carmack SA, Wood SC, Anagnostaras SG. 2010. Amphetamine and extinction of cued fear. Neurosci Lett 468: 18-22.
16. Carmack SA, Kim JS, Sage JR, Thomas AW, Skillicorn KN, Anagnostaras SG. 2013. The competitive NMDA receptor antagonist CPP disrupts cocaine-induced conditioned place preference, but spares behavioral sensitization. Behav Brain Res 239: 155-163.
17. Challman TD, Lipsky JJ. 2000. Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 75: 711-721.
18. Delgado MR, Olsson A, Phelps EA. 2006. Extending animal models of fear conditioning to humans. Biol Psychol 73: 39-48.
19. de Oliveira AR, Reimer AE, de Macedo CEA, de Carvalho MC, Silva MA, Brandão ML. 2011. Conditioned fear is modulated by D2 receptor pathway connecting the ventral tegmental area and basolateral amygdala. Neurobiol Learn Mem 95: 37-45.
20. Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, et al. 2013. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs doi: 10.1007/s40263-013-0104-8.
21. Dommett EJ, Henderson EL, Westwell MS, Greenfield SA. 2008. Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms. Learn Mem 15: 580-586.
22. Eagle DM, Tufft MR, Goodchild HL, Robbins TW. 2007. Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology 192: 193-206.
23. Ellinwood EH, King G, Lee T. 1998. Chronic amphetamine use and abuse. In Psychopharmacology: The fourth generation of progress (ed. Watson SJ), http://www.acnp.org/g4/gn401000166/ch162.htm. Lippincott, Williams & Wilkins, Philadelphia, PA.
24. Faraone SV, Wigal SB, Hodgkins P. 2007. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord 11: 74-82.
25. Fone KCF, Nutt DJ. 2005. Stimulants: Use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 5: 87-93.
26. Forest Laboratories. 2011. Celexa: Full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020822s038s040, 021046s016s017lbl.pdf.
27. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. 1999. Role of serotonin in the paradoxical calming effect ofpsychostimulants on hyperactivity. Science 283: 397-401.
28. Gale GD, Anagnostaras SG, Godsil BP, Mitchell S, Nozawa T, Sage JR, Wiltgen B, Fanselow MS. 2004. Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats. J Neurosci 24: 3810-3815
29. GlaxoSmithKline. 2013. Wellbutrin: Full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/018644s043lbl.pdf.
30. Han DD, Gu HH. 2006. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 6.
31. Humby T, Eddy JB, Good MA, Reichelt AC, Wilkinson LS. 2013. A novel translational assay of response inhibition and impulsivity: Effects of prefrontal cortex lesions, drugs used in ADHD, and serotonin 2C receptor antagonism. Neuropsychopharmacology 38: 2150-2159.
32. Johansen JP, Cain CK, Ostroff LE, LeDoux JE. 2011. Molecular mechanisms of fear learning and memory. Cell 147: 509-524.
33. Kuczenski R, Segal DS. 1997. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 68: 2032-2037.
34. Kuczenski R, Segal DS. 2002. Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22: 7264-7271.
35. Lazzaro SC, Hou M, Cunha C, Ledoux JE, Cain CK. 2010. Antagonism of lateral amygdala a1-adrenergic receptors facilitates fear conditioning and long-term potentiation. Learn Mem 17: 489-493.
36. LeDoux J. 1998. Fear and the brain: Where have we been, and where are we going? Biol Psychiatry 44: 1229-1238.
37. Mahan AL, Ressler KJ. 2012. Fear conditioning, synaptic plasticity and the amygdala: Implications for posttraumatic stress disorder. Trends Neurosci 35: 24-35.
38. Maren S. 2008. Pavlovian fear conditioning as a behavioral assay for hippocampus and amygdala function: Cautions and caveats. Eur J Neurosci 28: 1661-1666.
39. Marshall P, Schroeder R, O'Brien J, Fischer R, Ries A, Blesi B, Barker J. 2010. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. Clin Neuropsychol 24: 1204-1237.
40. McNeil Pediatrics. 2008. Concerta: Full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021121s015s017lbl.pdf.
41. Mehta MA, Goodyer IM, Sahakian BJ. 2004. Methylphenidate improves working memory and set-shifting in AD/HD: Relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293-305.
42. Morgan MA, LeDoux JE. 1995. Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Behav Neurosci 109: 681-688.
43. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Michelson D. 2008. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165: 721-730.
44. O'Toole K, Abramowitz A, Morris R, Dulcan M. 1997. Effects of methylphenidateonattention and nonverbal learning in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36: 531-538.
45. Puumala T, Ruotsalainen S, Jäkälä P, Koivisto E, Riekkinen P, Sirviö J. 1996. Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder. Neurobiol Learn Mem 66: 198-211.
46. Rapoport JL, Inoff-Germain G. 2002. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: Update 2002. J Atten Disord 6: S57-S60.
47. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. 1980. Dextroamphetamine: It's cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37: 933-943.
48. Rhodes SM, Park J, Seth S, Coghill DR. 2012. A comprehensive investigation of memory impairment in attention deficit hyperactivity disorder and oppositional defiant disorder. J Child Psychol Psychiatry 53: 128-137.
49. Richelson E, Pfenning M. 1984. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277-286.
50. Robbins TW. 2002. The 5-choice serial reaction time task: Behavioural pharmacology and functional neurochemistry. Psychopharmacology 163: 362-380.
51. Robinson TE, Berridge KC. 1993. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 18: 247-291.
52. Robinson TE, Berridge KC. 2003. Addiction. Ann Rev Psychol 54: 25-53.
53. Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH. 2013. Treatment persistence in attention deficit hyperactivity disorder: A retrospective analysis of patients initiated on lisdexamfetamine vs other medications. J Med Econ 16: 1275-1289.
54. Shuman T, Wood SC, Anagnostaras SG. 2009. Modafinil and memory: Effects of modafinil on Morris water maze learning and Pavlovian fear conditioning. Behav Neurosci 123: 257-266.
55. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. 1996. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35: 409-432.
56. Swanson J, Baler RD, Volkow ND. 2011. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: A decade of progress. Neuropsychopharmacology 36: 207-226.
57. Tye KM, Tye LD, Cone JJ, Hekkelman EF, Janak PH, Bonci A. 2010. Methylphenidate facilitates learning-induced amygdala plasticity. Nat Neurosci 13: 475-481.
58. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, et al. 2005. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9: 275-289.
59. Wong DT, Threlkeld PG, Best KL, Bymaster FP. 1982. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222: 61-65.
60. Wood SC, Anagnostaras SG. 2009. Memory and psychostimulants: Modulation of Pavlovian fear conditioning by amphetamine in C57BL/6 mice. Psychopharmacology 202: 197-206.
61. Wood SC, Anagnostaras SG. 2011. Interdependence of measures in pavlovian conditioned freezing. Neurosci Lett 505: 134-139.
62. Wood SC, Fay J, Sage JR, Anagnostaras SG. 2007. Cocaine and Pavlovian fear conditioning: Dose-effect analysis. Behav Brain Res 176: 244-250.
63. Wood SC, Sage JR, Shuman T, Anagnostaras SG. 2013. Psychostimulants and cognition: A continuum of behavioral and cognitive activation. Pharmacol Rev (in press).